“Moreover, in the observational cohort study 88% of children treated with remestemcel-L had severe disease with highest mortality risk, defined by either IBMTR Grade C/D or Glucksberg Grade III/IV, whereas only 22% to 68% of patients in the other studies were considered to be severe.“
MSB - taking on the worst of the worst - and succeeding.
Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel, page-3
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.010(0.93%) |
Mkt cap ! $1.244B | |||
| Open | High | Low | Value | Volume |
| $1.07 | $1.10 | $1.05 | $4.880M | 4.545M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 54894 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 24700 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
0.010 ( 0.40 %) |
||||
| Open | High | Low | Volume | ||
| $1.07 | $1.10 | $1.05 | 1011230 | ||
| Last updated 15.59pm 17/06/2024 ? | |||||
| MSB (ASX) Chart |
